Novartis pads case for new MS blockbuster with disease-progression analysis
admin 20th April 2018 Uncategorised 0Novartis is hoping its multiple sclerosis candidate siponimod’s performance in secondary progressive patients can help secure it a blockbuster approval. And now it has more data to put toward that case.
More: Novartis pads case for new MS blockbuster with disease-progression analysis
Source: fierce